In this study, we discovered that RBM15‐mediated m6A modification of SRSF1 inhibited cuproptosis via ATP7B alternative splicing in NSCLC; which may provide a new therapeutic target for NSCLC treatment. This evidence concerns the gene SRSF1 and non-small cell lung carcinoma.